Friday, 18 Jan 2019

You are here

FIELD Study: Fenofibrate Reduces Uric Acid and Gout Risk

Lancet reports the results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study - where fenofibrate was shown to reduce uric acid by 20%, gout events by nearly 50% and may be useful in preventing gout in diabetes. 

In the study, 9795 adults (age 50–75 years) with type 2 diabetes were randomized to receive fenofibrate 200 mg per day or placebo and followed for up to 5 years.

In the fenofibrate group, serum uric acid levels fell by 20·2% during a 6-week active fenofibrate run-in period (a reduction of 0·06 mmol/L or 1 mg/dL) and remained −20·1% (p<0·0001) lower for those re-measured at 1 year.

First new gout events were seen in 3% of placebo and 2% of fenofibrate patients during 5 years of follow-up (HR 0·54, 95% CI 0·41–0·70; p<0·0001).

Cumulative gout attacks were higher In the placebo group based on baseline uric acid concentration (7·7% or 13.9% if higher than 0·36 mmol/L or 0·42 mmol/L) versus only 3·4% or 5·7% in the fenofibrate group.

Analyzing all gout events, fenofibrate reduced the risk of gout events by 52% (HR 0·48, 95% CI 0·37–0·60; p<0·0001) compared with placebo.

Previous small and short term studies have shown fenofibrate to lower uric acid and reduces gout attacks.  The current study shows a sustained 20% reduction in uric acid levels that translates to fewer cases of incident gout in those with diabetes.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Febuxostat Gets Reprieve from FDA Advisory Panel

On January 11, 2019 the FDA convened two advisory panels (the Arthritis Advisory Committee [AAC] and the Drug Safety and Risk Management Advisory Committee [DSaRM]) to consider the cardiovascular safety of febuxostat (Uloric) based on the 2018 “Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) study. 

The Vote

Only One-Third of Gout Patients Receive Urate-Lowering Drugs

The most recent analysis of National Health and Nutrition Examination Survey [NHANES] 2007-2016) data shows the prevalence of gout to be 9.3 million in the USA.

Data from 5,467 participants from NHANES 2015-2016, finds gout in 3.9% or  9.2 million US adults.  This includes 5.2% [5.9 million] of men and 2.7% [3.3 million] of  women with gout.

Sleep Apnea Increases Gout Risk

Both Gout and obstructive sleep apnea (OSA) comingle with a wide range of serious comorbidities. A matched retrospective cohort study from the UK Clinical Practice Research database shows those with OSA are at a higher risk of developing gout.

This report compared 15,879 patients with OSA versus 63,296 without; median follow‐up was 5.8 years.

Hepatic Safety of Urate Lowering Therapies in Gout

Lee and a group of Korean investigators have analyzed the comparative safety of allopurinol and febuxostat in a small cohort of gout patients with fatty liver disease (FLD) and found febuxostat had a lower risk for hepatotoxicity (defined as AST or ALT at least 3× the upper limit of normal) compared to allopurinol.

Treat-to-Target Strategy Cuts Mortality in Gout Patients

More intense treatment of gout with a treat-to-target strategy can reduce patients' risk for death, a Spanish researcher told a press conference Monday at the American College of Rheumatology annual meeting here.